GO:0036379 myofilament: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036379 myofilament describes the smallest contractile unit of a myofibril in striated muscle, built from actin, myosin, tropomyosin, troponin and accessory proteins.
• Myofilament function depends on length-dependent activation and Ca2+ sensitivity, which tune force production across sarcomere lengths.
• Mutations in myofilament protein genes are a major cause of hypertrophic cardiomyopathy and influence patient outcome.
• Increased myofilament Ca2+-sensitivity is linked to arrhythmia susceptibility, making myofilament proteins electrical as well as mechanical effectors.
• Myofilament dysfunction contributes to cardiac disease from mouse models to humans, including diabetic cardiomyopathy via glycation.
• CRISPR knockout, point-mutation, knock-in and overexpression models are key tools for dissecting myofilament gene function and disease mechanisms.
Description
The Gene Ontology cellular component term GO:0036379, myofilament, defines any of the smallest contractile units of a myofibril in striated muscle fibers. Myofilaments are the operational engines of muscle contraction, converting chemical energy and calcium signals into mechanical force through the coordinated action of actin, myosin and their regulatory partners. Because the myofilament is the final common pathway for force generation, its protein composition, assembly and regulation are central to understanding both normal muscle physiology and disease. Researchers study myofilaments to explain how sarcomeric proteins set contractile performance, how mutations alter force and calcium handling, and how post-translational modifications such as glycation impair contraction in metabolic disease. The term is therefore essential for annotating genes and processes in cardiac and skeletal muscle biology, and for interpreting functional genomics screens that target contractile machinery.
myofilament At A Glance
| GO ID | GO:0036379 |
|---|---|
| GO term | myofilament |
| Ontology | cellular_component |
| Synonym | striated muscle filament |
| Definition | Any of the smallest contractile units of a myofibril (striated muscle fiber). |
| Major function | Force generation and regulation of contraction in striated muscle through actin-myosin interactions and calcium-dependent regulatory proteins. |
| Key components | Actin, myosin, tropomyosin, troponin and accessory proteins such as myosin-binding protein C. |
| Regulatory property | Length-dependent activation and Ca2+ sensitivity modulate force output. |
| Disease relevance | Mutations and modifications in myofilament proteins cause or modify cardiomyopathy, arrhythmia and diabetic contractile dysfunction. |
What Is GO:0036379?
GO:0036379 myofilament is defined as any of the smallest contractile units of a myofibril, the striated muscle fiber structure responsible for contraction. In practice, a myofilament is the ordered assembly of thin filaments, composed mainly of actin, tropomyosin and troponin, and thick filaments, composed mainly of myosin, together with accessory proteins that regulate and stabilize the contractile apparatus. The term captures the structural and functional unit whose sliding and regulatory interactions produce force, rather than the entire sarcomere or myofibril.
Why Is myofilament Important in Cell Biology?
Myofilaments are important because they are the ultimate effectors of muscle contraction, and their molecular properties determine how force is generated, regulated and adapted in health and disease. Small changes in myofilament protein sequence, isoform composition or post-translational modification can shift calcium sensitivity, alter relaxation kinetics and predispose to cardiomyopathy or arrhythmia. Consequently, myofilament biology bridges biophysics, genetics and clinical cardiology, and it provides a tractable system for testing causal variants and therapeutic strategies in model systems.
• Myofilaments are the smallest contractile units of striated muscle and the direct source of mechanical force.
• Length-dependent activation of myofilaments underlies the Frank-Starling relationship and beat-to-beat adaptation.
• Myofilament Ca2+ sensitivity is a determinant of both contractility and arrhythmia susceptibility.
• Mutations in myofilament protein genes are common in hypertrophic cardiomyopathy and affect clinical outcome.
• Myofilament dysfunction is observed in cardiac disease from mouse models to humans.
• Glycation of myofilament proteins in diabetes reduces contractility by inhibiting tropomyosin movement.
• Myofilament proteins are targets for functional genomics and CRISPR-based disease modeling.
• Biophysical studies of myofilament proteins inform drug discovery for sarcomeric cardiomyopathies.
• Regional variation in myofilament length-dependent activation contributes to chamber-specific physiology.
• Myofilament research integrates structural biology, physiology and genetics across species.
What Happens During myofilament?
Calcium-dependent activation
In simple terms: Calcium acts like a switch that turns on the myofilament.
In striated muscle, calcium binding to troponin moves tropomyosin away from myosin-binding sites on actin, permitting cross-bridge cycling and force generation. The sensitivity of this switch to calcium is a defining property of the myofilament and can be altered by disease-causing mutations or post-translational modifications.
Cross-bridge cycling and sliding
In simple terms: Myosin heads pull on actin filaments to shorten the muscle.
Myosin heads bind actin, undergo a power stroke, and detach in an ATP-dependent cycle, causing thin and thick filaments to slide past each other. This sliding filament mechanism, first articulated by Andrew Huxley, remains the central framework for myofilament force generation and has been extended by multiscale biophysical studies.
Length-dependent activation
In simple terms: Stretching the muscle makes the myofilament more sensitive to calcium.
Myofilament length-dependent activation describes the increase in calcium sensitivity and force when sarcomeres are stretched, a property that contributes to the Frank-Starling mechanism. Regional variation in this property has been documented and may contribute to differences in contractile behavior across muscle types.
Regulation by accessory proteins
In simple terms: Helper proteins fine-tune how strongly and how fast the myofilament contracts.
Accessory proteins such as myosin-binding protein C modulate myofilament structure and kinetics, and their domains can rescue defects caused by glycation. Mutations in these regulatory components are found in patients with hypertrophic cardiomyopathy and can influence outcome.
Key Genes Involved in GO:0036379 myofilament
The following genes and proteins are core components or regulators of the myofilament and are frequently studied in cardiac and skeletal muscle research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYH7 | Beta-myosin heavy chain, thick filament motor | Mutations cause hypertrophic cardiomyopathy and alter force generation. |
| MYBPC3 | Myosin-binding protein C, thick filament regulator | Mutations are common in hypertrophic cardiomyopathy and affect myofilament kinetics. |
| TNNT2 | Cardiac troponin T, thin filament regulatory subunit | Mutations alter calcium sensitivity and are linked to cardiomyopathy. |
| TNNI3 | Cardiac troponin I, inhibitory subunit | Mutations affect myofilament calcium regulation and disease risk. |
| TPM1 | Alpha-tropomyosin, thin filament regulator | Mutations and glycation impair tropomyosin movement and contractility. |
| ACTC1 | Cardiac actin, thin filament core | Mutations cause cardiomyopathy and disrupt force transmission. |
| MYL2 | Regulatory myosin light chain | Mutations modulate myofilament calcium sensitivity and disease. |
| MYL3 | Essential myosin light chain | Mutations are associated with hypertrophic cardiomyopathy. |
| MYH6 | Alpha-myosin heavy chain | Isoform shifts affect myofilament performance and disease models. |
| TNNC1 | Cardiac troponin C, calcium-binding subunit | Mutations alter calcium binding and myofilament activation. |
| MYOZ2 | Myozenin 2, Z-disc and myofilament-associated protein | Links myofilament function to signaling and cardiomyopathy. |
| ACTN2 | Alpha-actinin 2, sarcomeric structural protein | Supports myofilament anchoring and disease modeling. |
| TTN | Titin, sarcomere scaffold and elasticity | Provides passive tension and interacts with myofilament proteins. |
| NEB | Nebulin, thin filament length regulator | Regulates thin filament architecture and contractile function. |
| MYL7 | Atrial myosin light chain | Contributes to chamber-specific myofilament properties. |
| MYBPC1 | Slow skeletal myosin-binding protein C | Modulates skeletal myofilament contraction. |
| TNNT1 | Slow skeletal troponin T | Regulates skeletal myofilament calcium sensitivity. |
| TPM3 | Slow skeletal tropomyosin | Affects thin filament regulation in skeletal muscle. |
How Is myofilament Regulated?
Myofilament function is regulated at multiple levels. Calcium binding to troponin controls the thin filament switch, and the sensitivity of this switch can be modified by mutations, isoform shifts and post-translational modifications such as glycation. Length-dependent activation provides mechanical feedback, so that stretch increases calcium sensitivity and force. Accessory proteins including myosin-binding protein C further tune cross-bridge kinetics and can rescue glycation-induced defects. Disease-associated mutations in myofilament genes can shift these regulatory set points, leading to altered contractility and arrhythmia susceptibility.
myofilament and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYH7 | Hypertrophic cardiomyopathy | Knock-in of patient mutation in cardiomyocytes |
| MYBPC3 | Hypertrophic cardiomyopathy and glycation rescue | Knockout and rescue with cMyBPC domains |
| TNNT2 | Cardiomyopathy and altered calcium sensitivity | Point-mutation knock-in in iPSC-derived cardiomyocytes |
| TPM1 | Cardiomyopathy and impaired tropomyosin movement | Overexpression of mutant tropomyosin |
| TNNI3 | Cardiomyopathy and arrhythmia susceptibility | Knockout and point-mutation models |
Hypertrophic cardiomyopathy
Mutations in myofilament protein genes, including MYH7, MYBPC3, TNNT2, TNNI3, TPM1 and ACTC1, are established causes of hypertrophic cardiomyopathy, and mutation screening is used to inform prognosis and management. The myofilament is therefore a central node for genotype-phenotype correlation in sarcomeric cardiomyopathies.
Arrhythmia susceptibility
Increased myofilament Ca2+-sensitivity has been linked to arrhythmia susceptibility, indicating that myofilament properties can influence electrical stability as well as mechanical performance. This connection makes myofilament calcium handling a target for mechanistic and therapeutic studies.
Diabetic cardiomyopathy and metabolic disease
Myofilament glycation in diabetes reduces contractility by inhibiting tropomyosin movement, and this defect can be rescued by cMyBPC domains. This illustrates how metabolic modifications of myofilament proteins contribute to contractile dysfunction.
Myofilament dysfunction across species
Myofilament dysfunction has been documented in cardiac disease from mice to men, supporting the use of animal and cellular models to dissect conserved mechanisms. Such models help translate biophysical findings into clinically relevant insights.
From myofilament-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a myofilament gene alter contractility? | CRISPR knockout in cardiomyocytes or muscle cell lines |
| Does a patient variant change calcium sensitivity? | Point-mutation knock-in in iPSC-derived cardiomyocytes |
| Can a rescue domain restore glycation-induced defects? | Knock-in or overexpression of cMyBPC domains |
| Where is a myofilament protein localized? | Tagged knock-in with fluorescent reporter |
| Does overexpression of a myofilament protein alter sarcomere structure? | Overexpression in primary or immortalized muscle cells |
| Which myofilament genes modify disease severity? | CRISPR library screening in muscle disease models |
How to Study the myofilament Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Skinned fiber mechanics | Force and calcium sensitivity | Testing myofilament mutations |
| Length-dependent activation assay | Force response to sarcomere stretch | Studying Frank-Starling mechanism |
| Genetic mutation screening | Presence of myofilament gene variants | Cardiomyopathy diagnostics and prognosis |
| Proteomic glycation profiling | Post-translational modifications | Diabetic cardiomyopathy research |
| Immunofluorescence imaging | Myofilament localization and structure | Sarcomere assembly studies |
| CRISPR knockout screening | Gene requirement for contractile function | Functional genomics of myofilament genes |
| iPSC-derived cardiomyocyte assays | Contractility and calcium handling | Disease modeling of patient variants |
| Cross-bridge kinetics measurements | Myosin-actin interaction dynamics | Biophysical mechanism studies |
Biophysical and mechanical assays
Biophysical and biomechanical assays measure force, calcium sensitivity and cross-bridge kinetics of myofilament proteins, providing direct readouts of contractile function. These approaches are essential for linking genotype to mechanical phenotype.
Calcium sensitivity and length-dependent activation measurements
Experiments that vary calcium concentration and sarcomere length quantify myofilament calcium sensitivity and length-dependent activation, revealing how mutations or modifications shift contractile set points.
Genetic screening and sequencing
Mutation screening of myofilament protein genes in patient cohorts identifies pathogenic variants and supports genotype-phenotype correlations in cardiomyopathy. Such studies are foundational for clinical translation.
Proteomics and post-translational modification analysis
Proteomic and biochemical methods detect modifications such as glycation on myofilament proteins and test whether they impair tropomyosin movement or contractility. These approaches connect metabolic state to myofilament function.
How CRISPR Can Be Used to Study GO:0036379 myofilament
Knockout
CRISPR knockout of myofilament genes in cardiomyocytes or muscle cell lines can reveal whether a gene is required for sarcomere assembly and contractile function. Such models help distinguish causal contributors from bystanders in muscle disease.
Point Mutation
Point-mutation knock-in models introduce patient-specific variants into myofilament genes to test effects on calcium sensitivity, force and arrhythmia susceptibility. These models are valuable for validating variant pathogenicity.
Knock-in
Tagged or reporter knock-in of myofilament genes enables visualization of protein localization and dynamics within the sarcomere. Knock-in can also be used to express rescue domains such as cMyBPC to test restoration of contractility.
Overexpression
Overexpression of wild-type or mutant myofilament proteins can model gain-of-function effects and disrupt sarcomere stoichiometry, providing insight into disease mechanisms. This approach is useful when mutations act dominantly.
How EDITGENE Supports myofilament Research
Researchers studying myofilament-related genes often need to determine whether a candidate gene is causally involved in contractile dysfunction or disease, and CRISPR-based models provide a direct way to test that causality. By combining knockout, point-mutation, knock-in and overexpression strategies with functional assays, it becomes possible to link specific myofilament variants to measurable changes in force, calcium sensitivity and cellular phenotype.
Contact EDITGENE today to design your custom CRISPR model for myofilament research.
Frequently Asked Questions About myofilament
What is GO:0036379 myofilament?
GO:0036379 myofilament is a Gene Ontology cellular component term describing any of the smallest contractile units of a myofibril in striated muscle, built from actin, myosin and regulatory proteins.
What genes are involved in myofilament function?
Key myofilament genes include MYH7, MYBPC3, TNNT2, TNNI3, TPM1, ACTC1, MYL2, MYL3 and TNNC1, many of which are linked to cardiomyopathy when mutated.
How does the myofilament generate force?
Force is generated by calcium-dependent cross-bridge cycling between myosin and actin, with regulatory proteins controlling the switch and accessory proteins tuning kinetics.
What is length-dependent activation of myofilaments?
Length-dependent activation is the increase in myofilament calcium sensitivity and force when sarcomeres are stretched, contributing to the Frank-Starling mechanism.
How are myofilament mutations linked to hypertrophic cardiomyopathy?
Mutations in myofilament protein genes are established causes of hypertrophic cardiomyopathy and are used in screening to inform patient outcome.
Can myofilament dysfunction cause arrhythmia?
Yes, increased myofilament Ca2+-sensitivity has been associated with arrhythmia susceptibility, linking contractile properties to electrical instability.
How does diabetes affect myofilaments?
Myofilament glycation in diabetes reduces contractility by inhibiting tropomyosin movement, and this can be rescued by cMyBPC domains.
What methods are used to study myofilaments?
Common methods include skinned fiber mechanics, calcium sensitivity assays, genetic screening, proteomics, imaging and CRISPR-based functional genomics.
What CRISPR models are useful for myofilament research?
Knockout, point-mutation knock-in, tagged knock-in and overexpression models in cardiomyocytes or muscle cell lines are widely used to test myofilament gene function.
Why is myofilament research important for drug discovery?
Because myofilament proteins directly determine contractile performance, they are targets for therapies aimed at sarcomeric cardiomyopathies and contractile dysfunction.
Conclusion
GO:0036379 myofilament defines the smallest contractile unit of striated muscle and sits at the center of force generation, calcium regulation and sarcomeric disease. Research spanning biophysics, genetics and clinical cardiology has shown that myofilament protein mutations and modifications can alter calcium sensitivity, contractility and arrhythmia risk. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with functional and proteomic assays, provide a rigorous path to test causality and to develop targeted interventions for myofilament-related disorders.
References
- 1. Olivotto I et al.. 2008. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy.. Mayo Clin Proc 83(6):630-8 PMID: 18533079
- 2. de Tombe PP et al.. 2010. Myofilament length dependent activation.. J Mol Cell Cardiol 48(5):851-8 PMID: 20053351
- 3. Regnier M. 2014. Biophysical and biomechanical properties of myofilament proteins.. Arch Biochem Biophys 552-553:1-2 PMID: 24890820
- 4. Powers JD et al.. 2021. The Sliding Filament Theory Since Andrew Huxley: Multiscale and Multidisciplinary Muscle Research.. Annu Rev Biophys 50:373-400 PMID: 33637009
- 5. Huke S et al.. 2010. Increased myofilament Ca2+-sensitivity and arrhythmia susceptibility.. J Mol Cell Cardiol 48(5):824-33 PMID: 20097204
- 6. Cazorla O et al.. 2011. Regional variation in myofilament length-dependent activation.. Pflugers Arch 462(1):15-28 PMID: 21336586
- 7. Hamdani N et al.. 2008. Myofilament dysfunction in cardiac disease from mice to men.. J Muscle Res Cell Motil 29(6-8):189-201 PMID: 19140019
- 8. Papadaki M et al.. 2022. Myofilament glycation in diabetes reduces contractility by inhibiting tropomyosin movement, is rescued by cMyBPC domains.. J Mol Cell Cardiol 162:1-9 PMID: 34487755
